Clinical Trials

Accrual Status
Limit to SWOG Trials

647 Results

View
Status Trial Number Title Activated Closed Accrual Phase Published
Closed S0000 SELECT (Selenium and Vitamin E Cancer Prevention Trial) 7/25/2001 6/24/2004 100% Published
Closed S0000A PREADVISE 5/17/2002 9/30/2009 72% Published
Closed S0000B SELECT Eye Endpoints (SEE) 7/1/2004 7/31/2015 Published
Closed S0000C RAS 6/4/2004 5/1/2007 94% Published
Closed S0000D Adenomatous Colorectal Polyps (ACP) 6/3/2008 5/28/2013 100% Published
Closed S0001 Glioblastoma Multiforme/Gliosarcoma 9/1/2001 11/15/2005 46% Published
Closed S0003 Carbo/Pac + Tirapazamine vs. Carbo/Pac in Adv. NSCLC; Selected IIIB & IV 11/15/2000 11/15/2002 72% Published
Closed S0004 Tirapazamine/Cis/Etopo/RT in Limited SCLC 10/15/2000 4/1/2002 60% Published
Closed S0007 Advanced, Recurrent, or Metastatic 11/1/2000 5/15/2003 100% Published
Closed S0008 High Dose IFN vs. Cis/Vinblastine/DTIC + IL-2 & IFN in High Risk Melanoma 8/1/2000 11/15/2007 90% Published
Closed S0009 OVARIAN 3/15/2001 2/1/2006 100% Published
Closed S0011 Squamous cell carcinoma 3/1/2003 7/1/2006 22% Published
Closed S0012 NEOADJUVANT: Standard AC vs. Weekly A and Daily Oral C + G-CSF 5/1/2001 12/1/2005 100% Published
Closed S0013 CERVICAL 9/15/2000 11/15/2003 36% Published
Closed S0014 NON-HODGKIN'S: CHOP with concurrent rituximab plus IFR 4/1/2000 1/15/2002 100% Published
Closed S0016 NON-HODGKIN'S: CHOP/rituximab vs. CHOP/tositumomab 3/1/2001 10/2/2008 100% Published
Closed S0019 NON-HODGKIN'S: ICE +/- Rituxan for Relapsed/Refractory CD20+ B-Cell NHL 10/15/2000 12/15/2001 2% Published
Closed S0023 Cis/VP-16/RT/Consol. Doc followed by ZD1839/Placebo /IIIA & selected IIIB NSCLC 6/15/2001 4/15/2005 74% Published
Closed S0026 IFN & Thalidomide in Disseminated Malignant Melanoma 11/1/2001 5/1/2003 62% Published
Closed S0027 Vinorel/Doc/Adv NSCLC/Age >=70 PS 0-1/PS 2 any age; Selected IIIB & IV 9/1/2001 7/1/2003 100% Published
Scroll Table